Moclobemide: a Reversible MAO-A-Inhibitor Showing Weaker Antidepressant Effect Than Clomipramine in a Controlled Multicenter Study

Antidepressant and unwanted effects of moclobemide and clomipramine were compared in a double-bind, randomised, in-patient, fixed-dose study with weekly ratings and drug level measurements. End point analysis on the basis of different depression ratings showed consistently a significantly weaker effect of moclobemide compared with clomipramine. (30 refs.)